Quest Diagnostics Stock Drops 4.29% on Proposed Medicare Rate Cuts

Key Facts

1Quest Diagnostics stock fell 4.29% to $234.38 in pre-market trading.

2The decline is driven by proposed CMS Medicare rate cuts for laboratory services effective 2027.

3The company is scheduled to release its Q3 2026 financial results on October 22, 2026.

Amid rising regulatory pressure on the healthcare sector, medical laboratory companies are facing headwinds from new government proposals. According to reports, Quest Diagnostics stock fell 4.29% to $234.38 in pre-market trading. The decline is driven by proposed CMS Medicare rate cuts for laboratory services effective 2027, which threatens the company's long-term revenue outlook.

These price movements reflect the market's response to regulatory risks affecting the broader industry, as the announcement of proposed cuts led to the stock underperforming the Nasdaq index. Per market data, DGX closed at $234.76 on September 22, 2026, touching an intra-day low of $227.24, signaling clear selling pressure following the CMS announcement.

Looking ahead, investors are awaiting the company's Q3 2026 financial results scheduled for release on October 22, 2026, for further clarity on financial performance. Based on prices at close September 22, 2026, the stock faces technical support near its recent low of $227.24, while developments regarding Medicare policies remain the primary catalyst for near-term sentiment.